Nevertheless, tumor growth remained unaltered in both the vehicle- and lenvatinib-treated groups, indicating that the observed growth arrest was attributable to the antiproliferative impact of PLXNC1 silencing. The gene discussed is PLXNC1; the disease is neoplasm.